- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02916524
Predicting Rehabilitation Outcomes in Bilingual Aphasia Using Computational Modeling (PROCoM)
April 13, 2021 updated by: Swathi Kiran, Boston University Charles River Campus
Double-blind Randomized Trial Investigating the Use of Computational Modeling to Predict Rehabilitation Outcomes in Bilingual Aphasia
The purpose of this investigation is to implement a computational model that can predict and optimize training and cross-language generalization patterns for bilingual persons with aphasia (BPA).
The proposed work will determine the best possible treatment program for each individual patient even before they are rehabilitated.
In addition, the computational model allows specification of variables such as age of acquisition, language exposure/proficiency, impairment and their systematic influence on a range of language rehabilitation outcomes.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nishaat Mukadam, MA
- Phone Number: 617-353-2706
- Email: mukadamn@bu.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94132
- Recruiting
- San Francisco State University
-
Contact:
- Teresa Gray, Ph.D
- Email: teresag@sfsu.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Boston University Sargent College
-
Contact:
- Nishaat Mukadam, MA
- Phone Number: 617-353-2706
- Email: mukadamn@bu.edu
-
Contact:
- Swathi Kiran, PhD
- Phone Number: 617-358-5478
- Email: kirans@bu.edu
-
Principal Investigator:
- Swathi Kiran, PhD
-
-
Texas
-
Austin, Texas, United States, 78757
- Recruiting
- Austin Speech Labs
-
Contact:
- Shilpa Shamapant, M.S., M.A. CCC/SLP
- Email: shilpa@austinspeechlabs.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Any number of years of education
- Bilingual: speaking both Spanish and English (or Chinese and English) with any degree of language proficiency prior to stroke
- Aphasia secondary to a left-hemisphere stroke (diagnosed by a neurologist on the basis of clinical CT/MRI imaging or medical reports)
- Aphasia resulting from stroke or dementia
- Naming deficits must be present with concurrent lexical/semantic impairment
- Visual and auditory acuity sufficient for all assessment and treatment procedures
- Ability to understand study and follow study procedures for the entire length of the study
Exclusion Criteria:
- Premorbid history of speech/language disorder
- Proficient in more than just Spanish and English (or Chinese and English)
- Overt, behaviorally noticeable, attentional limitations that interfere with completing the experimental tasks
- Active medical disease that may compromise participation (e.g., cancer undergoing acute treatment, unstable diabetes, renal or hepatic insufficiency, fluctuating systemic immunological disease such as systemic lupus erythematosis, etc.)
- Currently taking medications that are known to exert significant effects on cognitive processes, such as neuroleptics, steroids, anticholinesterase inhibitors, etc.
- Current drug or alcohol use or dependence that would interfere with adherence to study requirements, in the opinion of the principal investigator
- Inability or unwillingness of individual to give written informed consent
- Diagnosed with mental illness other than active depression
- Neurological condition other than that which resulted in aphasia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Model-based
Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
|
SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item).
Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants.
Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
|
|
Active Comparator: Model-opposite
Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
|
SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item).
Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants.
Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
|
|
No Intervention: Sub-Study: Computational Modeling for Bilingual Dementia and Semantic Decline
This is a sub-study aimed at building a computational model to simulate bilingual dementia and semantic decline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Word Retrieval Accuracy in both languages
Time Frame: Through study completion, an average of 10 weeks
|
Accuracy of naming of pictured treated and untreated items in both languages will be assessed in probes conducted separate from treatment.
Probes were conducted repeatedly throughout the study, from baseline (prior to treatment) to the end of treatment.
All naming responses were scored using as correct or incorrect.
A percentage accuracy was calculated for each set of items for every probe session.
Baseline probe scores were compared to end of treatment probe scores to obtain individual effect sizes for each sets of items for each participant (i.e., several effect sizes were calculated for each participant).
|
Through study completion, an average of 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psycholinguistic assessments of language processing in aphasia (PALPA) in both languages
Time Frame: Week 1 and up to 10 weeks
|
Reading single words and understanding spoken words
|
Week 1 and up to 10 weeks
|
|
Boston Naming Test (BNT) in both languages
Time Frame: Week 1 and up to 10 weeks
|
Naming pictured items
|
Week 1 and up to 10 weeks
|
|
Bilingual Aphasia Test (BAT) B and C in both languages
Time Frame: Week 1 and up to 10 weeks
|
Assesses each of the languages of a bilingual or multilingual individual with aphasia
|
Week 1 and up to 10 weeks
|
|
Western Aphasia Battery (WAB) in both languages
Time Frame: Week 1 and up to 10 weeks
|
Assesses the levels of impairment of aphasia
|
Week 1 and up to 10 weeks
|
|
Cognitive Linguistic Quick Test (CLQT) in both languages
Time Frame: Week 1 and up to 10 weeks
|
Assesses the contribution of cognitive deficits to language dysfunction
|
Week 1 and up to 10 weeks
|
|
Verbal fluency task (COWAT) in both languages
Time Frame: Week 1 and up to 10 weeks
|
Assesses general fluency
|
Week 1 and up to 10 weeks
|
|
Category fluency task in both languages
Time Frame: Week 1 and up to 10 weeks
|
Assesses category fluency
|
Week 1 and up to 10 weeks
|
|
Communication Effectiveness Index (CETI) for both languages
Time Frame: Week 1 and up to 10 weeks
|
Determines communication effectiveness by proxy
|
Week 1 and up to 10 weeks
|
|
Pyramids and Palm Trees Test (PAPT) 3 pictures version
Time Frame: Week 1 and up to 10 weeks
|
Assesses semantic processing ability
|
Week 1 and up to 10 weeks
|
|
Aphasia Bank
Time Frame: Week 1 and up to 10 weeks
|
Assesses discourse
|
Week 1 and up to 10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Swathi Kiran, PhD, Boston University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 20, 2018
Primary Completion (Anticipated)
July 31, 2021
Study Completion (Anticipated)
July 31, 2023
Study Registration Dates
First Submitted
September 16, 2016
First Submitted That Met QC Criteria
September 26, 2016
First Posted (Estimate)
September 27, 2016
Study Record Updates
Last Update Posted (Actual)
April 19, 2021
Last Update Submitted That Met QC Criteria
April 13, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4492E
- U01DC014922-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.